AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
AIM ImmunoTech(AIM) Newsfilter·2024-02-08 21:50AMP-518研究结果 - AIM ImmunoTech Inc.（NYSE:AIM）宣布了其第二阶段研究AMP-518的正面头条结果[1] - Ampligen组在疲劳PROMIS®评分方面表现优于安慰剂组[2] - Ampligen对六分钟步行测试的影响较安慰剂更显著[3]